Carvedilol beta-blockers

Description Results NMA

cardiac event (fatal and non fatal ) 0.55 [0.34; 0.89]

cardiovascular death 0.63 [0.11; 3.67]

fatal and nonfatal MI 0.52 [0.20; 1.32]

cardiac death 0.64 [0.11; 3.73]

reinfarction 0.47 [0.15; 1.50]

Carvedilol target dose 25 mg BID (n=77)

vs.

placebo (n=74)

Patients were subsequently withdrawn if the cardiac enzymes failed to show the typical pattern of acute myocardial necrosis¬

Double blind

Parallel groups

Sample size: 77/74

Primary endpoint: cardiovascular event

FU duration: 6 months

NYHA deterioration 1.23 [0.77; 1.97]

all cause death 0.77 [0.45; 1.34]

cardiovascular death 0.90 [0.49; 1.66]

death or HF hospitalisation 0.72 [0.49; 1.06]

hospitalisation for heart failure 0.70 [0.43; 1.15]

NYHA improvement 0.94 [0.68; 1.28]

all cause death 0.67 [0.54; 0.83]

death or HF hospitalisation 0.82 [0.74; 0.91]

hospitalisation for heart failure 0.67 [0.59; 0.76]

all cause death 0.78 [0.62; 0.97]

cardiovascular death 0.76 [0.60; 0.96]

death or HF hospitalisation 0.93 [0.83; 1.05]

hospitalisation for heart failure 0.86 [0.69; 1.09]

cardiovascular death 0.70 [0.42; 1.17]

Sudden death 0.87 [0.42; 1.79]

All cause death 0.45 [0.23; 0.86]

All cause death 0.75 [0.57; 0.99]

carvedilol target dose 25mg twice daily (n=207)

vs.

placebo (n=208)

Double blind

Parallel groups

Sample size: 207/208

Primary endpoint: Exercise tolerance, EF Morbidity 1 mortality

FU duration: 19 mo (range 18-24 mo)

carvedilol traget dose of 25 mg twice daily (n=1156)

vs.

placebo (n=1133)

Double blind

Parallel groups

Sample size: 1156/1133

Primary endpoint: all-cause mortality

FU duration: 10.4 months

carvedilol target dose 25mg twice daily (n=975)

vs.

placebo (n=984)

Double blind

Parallel groups

Sample size: 975/984

Primary endpoint: all-cause death or hospitalization

FU duration: 1.3 years

carvedilol (n=20)

vs.

placebo (n=20)

Sample size: 20/20

Primary endpoint: Hemodynamics

FU duration: 4 mo

carvedilol (n=36)

vs.

placebo (n=23)

Sample size: 36/23

Primary endpoint: Hemodynamics

FU duration: 4 mo

carvedilol 25 mg twice daily during 14 weeks (n=33)

vs.

placebo (n=16)

selection of patients tolerating during run-in period 12.5mg twice daily

Sample size: 33/16

Primary endpoint: Hemodynamics

FU duration: 3.5 mo

carvedilol (n=261)

vs.

placebo (n=84)

Double blind

Parallel groups

Sample size: 261/84

Primary endpoint: Exercise tolerance

FU duration: 6.5-8 mo

carvediloltarget dose 25 mg twice daily (n=696)

vs.

placebo (n=398)

nested dose-ranging protocol (6.25, 12.5, 25 mg twice daily) cocnerning 345 patients (32%)

Double blind

Parallel groups

Sample size: 696/398

Primary endpoint: Exercise tolerance

FU duration: 6.5 mo (1 day - 15.1 mo)

carvedilol (n=232)

vs.

placebo (n=134)

Double blind

Parallel groups

Sample size: 232/134

Primary endpoint: progression of heart failure

FU duration: 213 days (0.6 years)

carvedilol (n=70)

vs.

placebo (n=35)

Sample size: 70/35

Primary endpoint: Quality of life

FU duration: <8 mo

Carvedilol (n=554)

vs.

placebo (n=0)

Sample size: 554/0

Primary endpoint:

FU duration:

Carvedilol (n=1102)

vs.

placebo (n=0)

Sample size: 1102/0

Primary endpoint:

FU duration:

all cause death 0.99 [0.49; 2.03]

cardiovascular death 0.92 [0.45; 1.91]

hospitalisation for heart failure 0.75 [0.36; 1.53]

carvedilol (target 25 mg bid) (n=191)

vs.

enalapril (target 10 mg bid) (n=190)

ND

Sample size: 191/190

Primary endpoint: left ventricular remodelling

FU duration: 18 months

all cause death 0.86 [0.78; 0.94]

cardiovascular death 0.82 [0.74; 0.91]

death or HF hospitalisation 0.97 [0.93; 1.01]

carvedilol (target dose 25 mg twice daily) (n=1511)

vs.

metoprolol tartrate target dose 50 mg twice daily (n=1518)

Double blind

Parallel groups

Sample size: 1511/1518

Primary endpoint: all-cause mortality and the composite endpoint

FU duration: 4.83 years

Cardiovascular mortality 0.43 [0.28; 0.67]

cardiovascular event 0.42 [0.27; 0.65]

Carvedilol 50 mg/day (n=58)

vs.

matched placebo (n=56)

Sample size: 58/56

Primary endpoint:

FU duration: 12 months

Carvedilol 20 mg/day (n=57)

vs.

matched placebo (n=51)

Sample size: 57/51

Primary endpoint:

FU duration: